Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. (Record no. 17719472)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01796 a2200541 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250515104552.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 200803s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1468-2079 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1136/bjo.2007.123513 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Kreutzer, T C |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20080314 |
| 245 00 - TITLE STATEMENT | |
| Title | Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | The British journal of ophthalmology |
| Date of publication, distribution, etc. | Mar 2008 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 351-5 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial; Journal Article |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged, 80 and over |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Angiogenesis Inhibitors |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal, Humanized |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Bevacizumab |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Administration Schedule |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Fovea Centralis |
| General subdivision | pathology |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Injections |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Macular Edema |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Retinal Vein Occlusion |
| General subdivision | complications |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment Outcome |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Vascular Endothelial Growth Factor A |
| General subdivision | antagonists & inhibitors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Visual Acuity |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Vitreous Body |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Alge, C S |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wolf, A H |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kook, D |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Burger, J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Strauss, R |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kunze, C |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Haritoglou, C |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kampik, A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Priglinger, S |
| 773 0# - HOST ITEM ENTRY | |
| Title | The British journal of ophthalmology |
| Related parts | vol. 92 |
| -- | no. 3 |
| -- | p. 351-5 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1136/bjo.2007.123513">https://doi.org/10.1136/bjo.2007.123513</a> |
| Public note | Available from publisher's website |
No items available.